Vaxcyte said cash, cash equivalents and investments totaled USD 2.4 billion as of Dec. 31, 2025, versus USD 3.1 billion a year earlier. The company reported a Q4 2025 net loss of USD 246.5 million, with R&D expenses of USD 242.1 million and G&A expenses of USD 32.3 million; for FY 2025, net loss was USD 766.6 million on R&D expenses of USD 794.3 million and G&A expenses of USD 129.4 million. On the business side, Vaxcyte said it has three Phase 3 studies underway for its VAX-31 adult program (OPUS-1, OPUS-2 and OPUS-3), with OPUS-1 topline safety, tolerability and immunogenicity data expected in Q4 2026 and OPUS-2/OPUS-3 results expected in H1 2027. The company also said enrollment is complete in its VAX-31 infant Phase 2 dose-finding study (900 infants dosed), with topline data from the primary series and booster expected by the end of H1 2027. Vaxcyte added it plans to initiate a Phase 1 adult study for VAX-A1, its Group A Strep vaccine candidate, in 2026, and said it completed construction of a dedicated Lonza manufacturing facility, with USD 335.4 million in cumulative capital and facility buildout expenditures recorded as of Dec. 31, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602241605PRIMZONEFULLFEED9660443) on February 24, 2026, and is solely responsible for the information contained therein.
Comments